Mark J Clemons (Mark Clemons)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 40

Top Topics

Positive Breast Cancer

Palliative Care

Top Venues

Current oncology (Toronto, Ont.)

Journal of evaluation in clinical practice

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F K Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark J Clemons
Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study. Current oncology (Toronto, Ont.) 31 (3) (2024)
Sharon F McGee, Mark J Clemons, Gregory Russell Pond, Jean-Michel Caudrelier, Michelle Liu, Mashari Jemaan Alzahrani, Terry L Ng, Arif A Awan, Sandeep R Sehdev, John Hilton, Marie-France Savard, Lesley Fallowfield, Vikaash Kumar, Orit Freedman, Lisa Vandermeer, Brian Hutton, Jean-Marc Bourque
A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer. Current oncology (Toronto, Ont.) 31 (8) (2024)
Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F K Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark J Clemons
Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study. Current oncology (Toronto, Ont.) 31 (3) (2024)
Ana-Alicia Beltran-Bless, Mark J Clemons, Lisa Vandermeer, Khaled El Emam, Terry L Ng, Sharon McGee, Arif Ali Awan, Gregory Pond, Julie Renaud, Gwen Barton, Brian Hutton, Marie-France Savard
The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care. Current oncology (Toronto, Ont.) 31 (3) (2024)
Ana-Alicia Beltran-Bless, Mark J Clemons, Lisa Vandermeer, Khaled El Emam, Terry L Ng, Sharon McGee, Arif Ali Awan, Gregory Pond, Julie Renaud, Gwen Barton, Brian Hutton, Marie-France Savard
The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care. Current oncology (Toronto, Ont.) 31 (3) (2024)
Parvaneh Fallah, Lucas Clemons, Michelle Bradbury, Lisa Vandermeer, Mark J Clemons, Julie Renaud, Marie-France Savard
Evaluation of Unsolicited Feedback from Patients with Cancer and Their Families as a Strategy to Improve Cancer Care Delivery. Current oncology (Toronto, Ont.) 31 (5) (2024)
Parvaneh Fallah, Lucas Clemons, Michelle Bradbury, Lisa Vandermeer, Mark J Clemons, Julie Renaud, Marie-France Savard
Evaluation of Unsolicited Feedback from Patients with Cancer and Their Families as a Strategy to Improve Cancer Care Delivery. Current oncology (Toronto, Ont.) 31 (5) (2024)
Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F K Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark J Clemons
Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study. Current oncology (Toronto, Ont.) 31 (3) (2024)
Parvaneh Fallah, Lucas Clemons, Michelle Bradbury, Lisa Vandermeer, Mark J Clemons, Julie Renaud, Marie-France Savard
Evaluation of Unsolicited Feedback from Patients with Cancer and Their Families as a Strategy to Improve Cancer Care Delivery. Current oncology (Toronto, Ont.) 31 (5) (2024)
Ana-Alicia Beltran-Bless, Mark J Clemons, Lisa Vandermeer, Khaled El Emam, Terry L Ng, Sharon McGee, Arif Ali Awan, Gregory Pond, Julie Renaud, Gwen Barton, Brian Hutton, Marie-France Savard
The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care. Current oncology (Toronto, Ont.) 31 (3) (2024)
Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F K Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark J Clemons
Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study. Current oncology (Toronto, Ont.) 31 (3) (2024)
Sharon F McGee, Mark J Clemons, Gregory Russell Pond, Jean-Michel Caudrelier, Michelle Liu, Mashari Jemaan Alzahrani, Terry L Ng, Arif A Awan, Sandeep R Sehdev, John Hilton, Marie-France Savard, Lesley Fallowfield, Vikaash Kumar, Orit Freedman, Lisa Vandermeer, Brian Hutton, Jean-Marc Bourque
A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer. Current oncology (Toronto, Ont.) 31 (8) (2024)
Ana-Alicia Beltran-Bless, Mark J Clemons, Lisa Vandermeer, Khaled El Emam, Terry L Ng, Sharon McGee, Arif Ali Awan, Gregory Pond, Julie Renaud, Gwen Barton, Brian Hutton, Marie-France Savard
The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care. Current oncology (Toronto, Ont.) 31 (3) (2024)
Ana-Alicia Beltran-Bless, Mark J Clemons, Lisa Vandermeer, Khaled El Emam, Terry L Ng, Sharon McGee, Arif Ali Awan, Gregory Pond, Julie Renaud, Gwen Barton, Brian Hutton, Marie-France Savard
The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care. Current oncology (Toronto, Ont.) 31 (3) (2024)
Sharon F McGee, Mark J Clemons, Gregory Russell Pond, Jean-Michel Caudrelier, Michelle Liu, Mashari Jemaan Alzahrani, Terry L Ng, Arif A Awan, Sandeep R Sehdev, John Hilton, Marie-France Savard, Lesley Fallowfield, Vikaash Kumar, Orit Freedman, Lisa Vandermeer, Brian Hutton, Jean-Marc Bourque
A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer. Current oncology (Toronto, Ont.) 31 (8) (2024)
Michelle Bradbury, Marie-France Savard, Lisa Vandermeer, Lucas Clemons, Gregory Pond, John Hilton, Mark J Clemons, Sharon McGee
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. Current oncology (Toronto, Ont.) 30 (12) (2023)
Huijun Zhao, Gregory Pond, Demetrios Simos, Zhou Wang, Susan Robertson, Gurmit Singh, Lisa Vandermeer, Mark J Clemons, Christina Lynn Addison
Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer. Cancers 15 (3) (2023)
Michelle Bradbury, Marie-France Savard, Lisa Vandermeer, Lucas Clemons, Gregory Pond, John Hilton, Mark J Clemons, Sharon McGee
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. Current oncology (Toronto, Ont.) 30 (12) (2023)
Samer El Kababji, Nicholas Mitsakakis, Xi Fang, Ana-Alicia Beltran-Bless, Greg Pond, Lisa Vandermeer, Dhenuka Radhakrishnan, Lucy Mosquera, Alexander Paterson, Lois E Shepherd, Bingshu E Chen, William E Barlow, Julie R Gralow, Marie-France Savard, Mark J Clemons, Khaled El Emam
Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets. JCO clinical cancer informatics 7 (2023)
Michelle Bradbury, Marie-France Savard, Lisa Vandermeer, Lucas Clemons, Gregory Pond, John Hilton, Mark J Clemons, Sharon McGee
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. Current oncology (Toronto, Ont.) 30 (12) (2023)
Ricardo Fernandes, Terry L Ng, Mashari Jemaan Alzahrani, Jacques Raphael, Phillip Blanchette, Morgan Black, Carol Stober, Gregory R Pond, David Cella, Lisa Vandermeer, Mohammed Ibrahim, Mark J Clemons, null null
A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer. Current oncology (Toronto, Ont.) 30 (8) (2023)
Michelle Bradbury, Marie-France Savard, Lisa Vandermeer, Lucas Clemons, Gregory Pond, John Hilton, Mark J Clemons, Sharon McGee
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. Current oncology (Toronto, Ont.) 30 (12) (2023)
Michelle Bradbury, Marie-France Savard, Lisa Vandermeer, Lucas Clemons, Gregory Pond, John Hilton, Mark J Clemons, Sharon McGee
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. Current oncology (Toronto, Ont.) 30 (12) (2023)
Huijun Zhao, Gregory Pond, Demetrios Simos, Zhou Wang, Susan Robertson, Gurmit Singh, Lisa Vandermeer, Mark J Clemons, Christina Lynn Addison
Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer. Cancers 15 (3) (2023)
Michelle Bradbury, Marie-France Savard, Lisa Vandermeer, Lucas Clemons, Gregory Pond, John Hilton, Mark J Clemons, Sharon McGee
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. Current oncology (Toronto, Ont.) 30 (12) (2023)
Victoria Allen, Josée Coulombe, Huijun Zhao, Lauren M Kreps, David P Cook, Benjamin Pryce, Mark J Clemons, Barbara C Vanderhyden, Douglas A Gray, Christina Lynn Addison
VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models. British journal of cancer 127 (1) (2022)
Sharon F McGee, Mark J Clemons, Marie-France Savard
Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective. Current oncology (Toronto, Ont.) 29 (6) (2022)
Bader Alshamsan, Brian Hutton, Michelle Liu, Lisa Vandermeer, Mark J Clemons
Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program. Current oncology (Toronto, Ont.) 29 (12) (2022)
Bader Alshamsan, Brian Hutton, Michelle Liu, Lisa Vandermeer, Mark J Clemons
Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program. Current oncology (Toronto, Ont.) 29 (12) (2022)
Igal Kushnir, Mark J Clemons, Dean Fergusson, Dominick Bossé, Martin Neil Reaume
Attitudes towards open-label versus placebo-control designs in oncology randomized trials: A survey of medical oncologists. Journal of evaluation in clinical practice 28 (3) (2022)
Andrea Eisen, Mark R Somerfield, Melissa K Accordino, Phillip S Blanchette, Mark J Clemons, Sukhbinder Dhesy-Thind, Melissa S Dillmon, Stella D'Oronzo, Glenn G Fletcher, Elizabeth S Frank, Sigrun Hallmeyer, Issam Makhoul, Beverly Moy, Alia Thawer, Joy Y Wu, Catherine H Van Poznak
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (7) (2022)
Bader Alshamsan, Brian Hutton, Michelle Liu, Lisa Vandermeer, Mark J Clemons
Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program. Current oncology (Toronto, Ont.) 29 (12) (2022)
Bader Alshamsan, Brian Hutton, Michelle Liu, Lisa Vandermeer, Mark J Clemons
Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program. Current oncology (Toronto, Ont.) 29 (12) (2022)
Bader Alshamsan, Brian Hutton, Michelle Liu, Lisa Vandermeer, Mark J Clemons
Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program. Current oncology (Toronto, Ont.) 29 (12) (2022)
Marie-France Savard, Mashari Jemaan Alzahrani, Deanna Saunders, Lynn Chang, Angel Arnaout, Terry L Ng, Muriel Brackstone, Lisa Vandermeer, Tina Hsu, Ari Ali Awan, Katherine Cole, Gail Larocque, Mark J Clemons
Experiences and Perceptions of Older Adults with Lower-Risk Hormone Receptor-Positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey. Current oncology (Toronto, Ont.) 28 (6) (2021)
Ana-Alicia Beltran-Bless, Brent Vandermeer, Alexander Paterson, Ian Gunstone, Leonard Kaizer, Angel Arnaout, Lisa Vandermeer, Mark J Clemons
Lost in Transition? Thoughts on Retirement, Part 2. "Should I Stay or Should I Go Now?" The oncologist 26 (8) (2021)
Deanna Saunders, Michelle Liu, Lisa Vandermeer, Mashari Jemaan Alzahrani, Brian Hutton, Mark J Clemons
The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design. Current oncology (Toronto, Ont.) 28 (5) (2021)
Mashari Alzahrani, Mark J Clemons, Lynn Chang, Lisa Vendermeer, Angel Arnaout, Gail Larocque, Katherine Cole, Tina Hsu, Deanna Saunders, Marie-France Savard
Management Strategies for Older Patients with Low-Risk Early-Stage Breast Cancer: A Physician Survey. Current oncology (Toronto, Ont.) 29 (1) (2021)
Arif Awan, Bassam Basulaiman, Carol Stober, Mark J Clemons, Dean Fergusson, John Hilton, Waleed Al Ghareeb, Rachel Goodwin, Mohammed Ibrahim, Brian Hutton, Lisa Vandermeer, Ranjeeta Mallick, Michael M Vickers
Oral magnesium supplements for cancer treatment-induced hypomagnesemia: Results from a pilot randomized trial. Health science reports 4 (4) (2021)
Susan Dent, Dean Fergusson, Olexiy Aseyev, Carol Stober, Gregory Pond, Arif A Awan, Sharon F McGee, Terry L Ng, Demetrios Simos, Lisa Vandermeer, Deanna Saunders, John F Hilton, Brian Hutton, Mark J Clemons
A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. Current oncology (Toronto, Ont.) 28 (6) (2021)